These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 18476968)
1. Radiation in high-risk prostate cancer: how much is enough? Payne H BJU Int; 2008 Sep; 102(6):663-5. PubMed ID: 18476968 [No Abstract] [Full Text] [Related]
2. Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy. Dörr W; Jaal J; Zips D Strahlenther Onkol; 2007 Dec; 183 Spec No 2():14-5. PubMed ID: 18166999 [No Abstract] [Full Text] [Related]
3. Prostate displacement kit: reducing the radiation dose to the rectum. Kälkner KM; Nilsson J; Lundell M; Levitt S; Nilsson S Radiother Oncol; 2006 Dec; 81(3):291-3. PubMed ID: 17125860 [TBL] [Abstract][Full Text] [Related]
4. [A case of pyoderma gangrenosum involving the prostate gland after radiation therapy for prostate cancer]. Kanno T; Ito M; Tsuji H; Kawase N; Taki Y Hinyokika Kiyo; 2002 Sep; 48(9):565-8. PubMed ID: 12402485 [TBL] [Abstract][Full Text] [Related]
5. Toxicity and health-related quality-of-life assessment in prostate radiotherapy. Rodrigues G; Lock M; D'Souza D Can J Urol; 2007 Aug; 14(4):3608-15. PubMed ID: 17784980 [TBL] [Abstract][Full Text] [Related]
6. [Chronic gastrointestinal toxicity after external-beam radiation therapy for prostate cancer]. Sefrová J; Paluska P; Odrázka K; Jirkovský V Klin Onkol; 2009; 22(5):233-41. PubMed ID: 19886362 [TBL] [Abstract][Full Text] [Related]
10. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. Nguyen PL; D'Amico AV J Clin Oncol; 2008 Apr; 26(12):2055-6; author reply 2056-7. PubMed ID: 18421061 [No Abstract] [Full Text] [Related]
11. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. D'Ambrosio DJ; Pollack A; Harris EE; Price RA; Verhey LJ; Roach M; Demanes DJ; Steinberg ML; Potters L; Wallner PE; Konski A Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):671-7. PubMed ID: 18262085 [No Abstract] [Full Text] [Related]
12. [The patient chooses for feasibility and effectiveness]. Stalmeier PF; van Tol-Geerdink JJ; van Lin EN; Schimmel E; Huizenga H; van Daal WA; Leer JW Ned Tijdschr Geneeskd; 2009 Mar; 153(13):600-6. PubMed ID: 19408536 [No Abstract] [Full Text] [Related]
13. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
14. Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Jahraus CD; Rubin DT; Scherl EJ; Bettenhausen D Gastroenterology; 2005 Aug; 129(2):770-2. PubMed ID: 16083743 [No Abstract] [Full Text] [Related]
15. Re: Conservative management of early bladder rupture after postoperative radiotherapy for prostate cancer. Aherne NJ Urol J; 2009; 6(2):145. PubMed ID: 19472138 [No Abstract] [Full Text] [Related]
16. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488 [TBL] [Abstract][Full Text] [Related]
17. The need and prospect of individualized external beam radiotherapy dose escalation beyond 80 gy to treat prostate cancer: in regard to Eade et al. (Int J. Radiat. Oncol. Biol. Phys. 2007;68:682-689). Cheung MR Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):645; author reply 645-6. PubMed ID: 18207039 [No Abstract] [Full Text] [Related]
18. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Huo D; Hetzel JT; Roy H; Rubin DT Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678 [TBL] [Abstract][Full Text] [Related]
19. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306 [TBL] [Abstract][Full Text] [Related]
20. Radiotherapy for prostate cancer. Campo A N Engl J Med; 2007 Jan; 356(3):309; author reply 310-1. PubMed ID: 17236260 [No Abstract] [Full Text] [Related] [Next] [New Search]